Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $200M Series A (Mar 2026) at $2B+ valuation led by AON Consulting. 91%+ medication adherence. GLP-1 benefits platform for employers. Linda Yaccarino CEO.
eMed is a GLP-1 and metabolic health benefits platform built specifically for employer-sponsored health plans, the fastest-growing category in US workplace benefits. The company raised $200 million in Series A financing in March 2026 at a $2 billion+ valuation led by AON Consulting, with backing from Linda Yaccarino (former Twitter/X CEO, now eMed CEO) and Tom Brady. Claiming 91%+ medication adherence rates, eMed positions itself as the most effective GLP-1 benefits program available to employers.
Raised $300M (Mar 2026) led by Series X Capital. Became independent corporation; Alphabet now minority investor. Partners include Samsung Galaxy Watch 8 and Salesforce.
Verily is a precision health AI company that became independent from Alphabet (Google's parent) in March 2026 when it raised $300 million led by Series X Capital, transitioning Alphabet to a minority investor. The independence marks a major strategic inflection: Verily now competes as a standalone health AI platform rather than operating as a Google moonshot project, with the commercial accountability that comes with external capital and institutional investors.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.